<code id='F11502370C'></code><style id='F11502370C'></style>
    • <acronym id='F11502370C'></acronym>
      <center id='F11502370C'><center id='F11502370C'><tfoot id='F11502370C'></tfoot></center><abbr id='F11502370C'><dir id='F11502370C'><tfoot id='F11502370C'></tfoot><noframes id='F11502370C'>

    • <optgroup id='F11502370C'><strike id='F11502370C'><sup id='F11502370C'></sup></strike><code id='F11502370C'></code></optgroup>
        1. <b id='F11502370C'><label id='F11502370C'><select id='F11502370C'><dt id='F11502370C'><span id='F11502370C'></span></dt></select></label></b><u id='F11502370C'></u>
          <i id='F11502370C'><strike id='F11502370C'><tt id='F11502370C'><pre id='F11502370C'></pre></tt></strike></i>

          
          WSS
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

          advertisement

          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive